# US 2012/0251584 A1 · Combination pharmaceutical composition and methods of treating diseases or conditions associated with the cardiovascular system

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2012/0251584 A1
- Document ID: US20120251584A1
- Status: Published application
- Kind: A1
- Application number: 13/135,882
- Filed: 2011-07-15
- Published: 2012-10-04
- Earliest claimed: 2010-07-15
- Assignees: Oleg I. Epshtein
- Inventors: Oleg Iliich Epshtein; Svetlana Alexandrovna Sergeeva; Liudmila Fyodorovna Dolgovyh; Vladmir Ivanovich Petrov
- Web page: https://patentgrep.com/patent/US20120251584A1

## CPC

- C07K 16/2869: {against hormone receptors (for antibodies against neuromediator receptors C07K16/286)}
- A61K 41/0004: {Homeopathy; Vitalisation; Resonance; Dynamisation, e.g. esoteric applications; Oxygenation of blood}
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61P 7/02: Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
- A61P 9/00: Drugs for disorders of the cardiovascular system
- A61P 9/02: Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
- A61P 9/04: Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
- A61P 9/12: Antihypertensives
- A61P 25/22: Anxiolytics
- A61P 25/24: Antidepressants
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C07K 16/40: against enzymes
- A61K 2039/505: {comprising antibodies}
- A61K 2039/507: {Comprising a combination of two or more separate antibodies}
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The present application provides a pharmaceutical composition for administration to a patient suffering from at least one symptom of a cardiovascular condition, the composition comprising a) an activated-potentiated form of an antibody to angiotensin II AT1 receptor, and b) an activated-potentiated form of an antibody to endothelial NO-synthase.

## Claims

### Claim 1

A combination pharmaceutical composition for administration to a patient suffering from at least one symptom of a cardiovascular condition, said composition comprising a) an activated-potentiated form of an antibody to angiotensin II AT1 receptor, and b) an activated-potentiated form of an antibody to endothelial NO-synthase.

### Claim 2 (depends on 1)

The combination pharmaceutical composition of claim 1, wherein said activated-potentiated form of an antibody to angiotensin II AT1 receptor is an activated-potentiated form of an antibody to the C-terminal fragment of the angiotensin II AT1 receptor.

### Claim 3 (depends on 1)

The combination pharmaceutical composition of claim 1, wherein said cardiovascular condition is associated with a reduced quality of life of said patient and wherein said administration of said pharmaceutical composition to said patient improves said quality of life of said patient.

### Claim 4 (depends on 1)

The combination pharmaceutical composition of claim 1, wherein said activated-potentiated form of an antibody to angiotensin II AT1 receptor is in the form of a C12, C30, or C200 homeopathic dilution or a mixture thereof.

### Claim 5 (depends on 1)

The combination pharmaceutical composition of claim 1, wherein said activated-potentiated form of an antibody to angiotensin II AT1 receptor is in the form of a mixture of C12, C30, and C200 homeopathic dilutions impregnated onto a solid carrier.

### Claim 6 (depends on 1)

The combination pharmaceutical composition of claim 1, wherein said activated-potentiated form of an antibody to endothelial NO-synthase is in the form of a C12, C30, or C200 homeopathic dilution or a mixture thereof.

### Claim 7 (depends on 1)

The combination pharmaceutical composition of claim 1, wherein said activated-potentiated form of an antibody to endothelial NO-synthase is in the form of mixture of C12, C30, and C200 homeopathic dilutions impregnated onto a solid carrier.

### Claim 8 (depends on 1)

The combination pharmaceutical composition of claim 1, which is prepared by impregnating a solid carrier with a mixture of i) said activated-potentiated form of an antibody to endothelial NO-synthase is in the form of mixture of C12, C30, and C200 homeopathic dilutions, and ii) said activated-potentiated form of an antibody to angiotensin II AT1 receptor is in the form of mixture of C12, C30, and C200 homeopathic dilutions.

### Claim 9 (depends on 1)

The combination pharmaceutical composition of claim 1, wherein said activated-potentiated form of an antibody to angiotensin II AT1 receptor is a monoclonal, polyclonal or natural antibody.

### Claim 10 (depends on 9)

The combination pharmaceutical composition of claim 9, wherein said activated-potentiated form of an antibody to angiotensin II AT1 receptor is a polyclonal antibody.

### Claim 11 (depends on 8)

The combination pharmaceutical composition of claim 8, wherein said activated-potentiated form of an antibody to angiotensin II AT1 receptor is prepared by successive centesimal dilutions coupled with shaking of every dilution.

### Claim 12 (depends on 1)

The combination pharmaceutical composition of claim 1, wherein said activated-potentiated form of an antibody to endothelial NO-synthase is a monoclonal, polyclonal or natural antibody.

### Claim 13 (depends on 12)

The combination pharmaceutical composition of claim 12, wherein said activated-potentiated form of an antibody to endothelial NO-synthase is a polyclonal antibody.

### Claim 14 (depends on 8)

The combination pharmaceutical composition of claim 8, wherein said activated-potentiated form of an antibody to endothelial NO-synthase is prepared by successive centesimal dilutions coupled with shaking of every dilution.

### Claim 15

A method of treating a patient suffering from a reduced overall quality of life associated with at least one symptom of a cardiovascular condition, said method comprising administering to said patient substantially at the same time a) an activated-potentiated form of an antibody to angiotensin II AT1 receptor, and b) an activated-potentiated form of an antibody to endothelial NO-synthase, thereby said administration improves said overall quality of life of said patient.

### Claim 16 (depends on 15)

The method of claim 15, wherein said activated-potentiated form of an antibody to angiotensin II AT1 receptor is an activated-potentiated form of an antibody to the C-terminal fragment of the angiotensin II AT1 receptor.

### Claim 17 (depends on 15)

The method of claim 15 wherein said a) an activated-potentiated form of an antibody to angiotensin II AT1 receptor, and b) an activated-potentiated form of an antibody to endothelial NO-synthase are administered in the form of a combined pharmaceutical composition.

### Claim 18 (depends on 15)

The method of claim 15, further comprising concomitantly administering to said patient an additional therapeutic agent suitable for administration to patients suffering from said at least one symptom of a cardiovascular condition.

### Claim 19 (depends on 18)

The method of claim 18, wherein said additional therapeutic agent is selected from the group consisting of ACE inhibitors, diuretics; 6-adrenergic blockers, nitrates, cardiac glycosides, calcium antagonists, hypolipidemic agents, antiaggregants, antihypoxants, and anticoagulants.

### Claim 20 (depends on 19)

The method of claim 19, wherein said additional therapeutic agent is bisoprol, enalapril or aspirin.

### Claim 21 (depends on 15)

The method of claim 15 wherein said patient is administered said composition in the form of a solid unit dosage form comprising said activated-potentiated form of an antibody to angiotensin II AT1 receptor and said activated-potentiated form of an antibody to endothelial NO-synthase.

### Claim 22 (depends on 21)

The method of claim 21, wherein said patient is administered one to two of said unit dosage forms, each administration carried out from once daily to four times daily.

### Claim 23 (depends on 15)

The method of claim 15, which comprises administration of from one to two unit dosage forms of said activated-potentiated form of an antibody to angiotensin II AT1 receptor, and from one to two unit dosage forms of said activated-potentiated form of an antibody to endothelial NO-synthase, each of said dosage forms being administered from once daily to four times daily.

### Claim 24 (depends on 23)

The method of claim 23, wherein each of said unit dosage form is administered twice daily.

### Claim 25 (depends on 15)

The method of claim 15, wherein said cardiovascular condition is chronic heart failure.

### Claim 26 (depends on 15)

The method of claim 15, wherein said patient exhibits statistically significant improvement in rigidity parameters of carotid radial artery segments upon said administration.

### Claim 27 (depends on 15)

The method of claim 15, wherein said cardiovascular condition is asthenia and/or vegetative vascular dystonia.

### Claim 28 (depends on 27)

The method of claim 27, wherein said administration of said combination leads to a statistically significant improvement in the mental asthenia by the MFI-20 scale in a suitable population of said patients in reference to the baseline.

### Claim 29 (depends on 27)

The method of claim 27, wherein said administration of said combination leads to a statistically significant reduction in the general asthenia by the MFI-20 scale in a suitable population of said patients in reference to the baseline.

### Claim 30 (depends on 15)

The method of claim 15, wherein said reduced overall quality of life is associated with anxiety related to said cardiovascular condition.

### Claim 31 (depends on 30)

The method of claim 30, wherein said administration of said combination leads to a statistically significant improvement in the Minnesota Total Inventory Score in a suitable population of said patients in reference to the baseline.

### Claim 32 (depends on 15)

The method of claim 15, wherein said reduced overall quality of life is associated with depression related to said cardiovascular condition.

### Claim 33 (depends on 32)

The method of claim 32, wherein said administration of said combination leads to a statistically significant reduction in the Beck Questionnaire Score in a suitable population of said patients in reference to the baseline.

### Claim 34 (depends on 15)

The method of claim 15, wherein said activated-potentiated form of an antibody to angiotensin II AT1 receptor is a monoclonal, polyclonal or natural antibody.

### Claim 35 (depends on 15)

The method of claim 15, wherein said activated-potentiated form of an antibody to angiotensin II AT1 receptor is a polyclonal antibody.

### Claim 36 (depends on 15)

The method of claim 15, wherein said activated-potentiated form of an antibody to endothelial NO-synthase is a monoclonal, polyclonal or natural antibody.

### Claim 37 (depends on 15)

The method of claim 15, wherein said activated-potentiated form of an antibody to endothelial NO-synthase is a polyclonal antibody.

### Claim 38

A method of treating a patient suffering from chronic heart failure, said method comprising administering to said patient a combination of a) an activated-potentiated form of an antibody to angiotensin II AT1 receptor, and b) an activated-potentiated form of an antibody to endothelial NO-synthase.

### Claim 39 (depends on 38)

The method of claim 38, wherein said activated-potentiated form of an antibody to angiotensin II AT1 receptor is an activated-potentiated form of an antibody to the C-terminal fragment of the angiotensin II AT1 receptor.

### Claim 40 (depends on 38)

The method of claim 38, further comprising concomitant administration to said patient of an additional therapeutic agent selected from the group consisting of ACE inhibitors, diuretics; 6-adrenergic blockers, nitrates, cardiac glycosides, calcium antagonists, hypolipidemic agents, antiaggregants, antihypoxants, and anticoagulants.

### Claim 41 (depends on 40)

The method of claim 40, wherein said therapeutic agent is selected from bisoprol, enalapril and aspirin.

### Claim 42 (depends on 38)

The method of claim 38, wherein said patient is administered said composition in the form of a solid unit dosage form comprising said activated-potentiated form of an antibody to angiotensin II AT1 receptor and said activated-potentiated form of an antibody to endothelial NO-synthase.

### Claim 43 (depends on 42)

The method of claim 42, wherein said patient is administered one to two of said unit dosage forms, each administration carried out from once daily to four times daily.

### Claim 44 (depends on 38)

The method of claim 38, which comprises administration of from one to two unit dosage forms of said activated-potentiated form of an antibody to angiotensin II AT1 receptor, and from one to two unit dosage forms of said activated-potentiated form of an antibody to endothelial NO-synthase, each of said dosage forms being administered from once daily to four times daily.

### Claim 45 (depends on 38)

The method of claim 38, wherein said patient exhibit statistically significant improvement in rigidity parameters of carotid radial artery segments upon said administration.

### Claim 46 (depends on 45)

The method of claim 45, wherein said patient exhibit statistically significant improvement in rigidity parameters of carotid femoral artery segments upon said administration.

### Claim 47 (depends on 38)

The method of claim 38, wherein said patient exhibits statistically significant reduction in anxiety associated with said chronic heart failure upon said administration.

### Claim 48 (depends on 47)

The method of claim 47, wherein said administration of said combination leads to a statistically significant improvement in the Minnesota Total Inventory Score in a suitable population of said patients in reference to the baseline.

### Claim 49 (depends on 47)

The method of claim 47, wherein said administration of said combination leads to a statistically significant reduction in the Kansas City Cardiomyopathy Questionnaire Total Score in a suitable population of said patients in reference to the baseline.

### Claim 50 (depends on 38)

The method of claim 38, wherein said administration of said combination leads to a statistically significant improvement in a 6-minute walking test score in a suitable population of said patients.

### Claim 51 (depends on 38)

The method of claim 38, wherein said administration of said combination leads to a statistically significant improvement in the HADS Total score in a suitable population of said patients.

### Claim 52 (depends on 38)

The method of claim 38, wherein said patient exhibits statistically significant reduction in depression associated with said chronic heart failure upon said administration.

### Claim 53 (depends on 38)

The method of claim 38, wherein said activated-potentiated form of an antibody to a C-terminal fragment of the angiotensin II AT1 receptor is a monoclonal, polyclonal or natural antibody.

### Claim 54 (depends on 53)

The method of claim 53, wherein said activated-potentiated form of an antibody to a C-terminal fragment of the angiotensin II AT1 receptor is a polyclonal antibody.

### Claim 55 (depends on 38)

The method of claim 38, wherein said activated-potentiated form of an antibody to endothelial NO-synthase is a monoclonal, polyclonal or natural antibody.

### Claim 56 (depends on 55)

The method of claim 55, wherein said activated-potentiated form of an antibody to endothelial NO-synthase is a polyclonal antibody.

### Claim 57

A method of treating a patient suffering from asthenia and/or vegetative-vascular dystonia, said method comprising administering to said patient a combination of a) an activated-potentiated form of an antibody to angiotensin II AT1 receptor, and b) an activated-potentiated form of an antibody to endothelial NO-synthase.

### Claim 58 (depends on 57)

The method of claim 57, wherein said activated-potentiated form of an antibody to angiotensin II AT1 receptor is an activated-potentiated form of an antibody to the C-terminal fragment of the angiotensin II AT1 receptor.

### Claim 59 (depends on 57)

The method of claim 57, further comprising concomitant administration to said patient of an additional therapeutic agent selected from the group consisting of ACE inhibitors, diuretics; β-adrenergic blockers, nitrates, cardiac glycosides, calcium antagonists, hypolipidemic agents, antiaggregants, antihypoxants, and anticoagulants.

### Claim 60 (depends on 59)

The method of claim 59, wherein said additional therapeutic agent is selected from bisoprol, enalapril and aspirin.

### Claim 61 (depends on 59)

The method of claim 59, wherein said patient is administered said composition in the form of a solid unit dosage form comprising said activated-potentiated form of an antibody to angiotensin II AT1 receptor and said activated-potentiated form of an antibody to endothelial NO-synthase.

### Claim 62 (depends on 61)

The method of claim 61, wherein said patient is administered one to two of said unit dosage forms, each administration carried out from once daily to four times daily.

### Claim 63 (depends on 59)

The method of claim 59, which comprises administration of from one to two unit dosage forms of said activated-potentiated form of an antibody to angiotensin II AT1 receptor, and from one to two unit dosage forms of said activated-potentiated form of an antibody to endothelial NO-synthase, each of said dosage forms being administered from once daily to four times daily.

### Claim 64 (depends on 63)

The method of claim 63, wherein said one to two unit dosage form of each of said activated-potentiated forms of antibodies is administered twice daily.

### Claim 65 (depends on 59)

The method of claim 59, wherein said patient exhibit statistically significant improvement in rigidity parameters of carotid radial artery segments upon said administration.

### Claim 66 (depends on 65)

The method of claim 65, wherein said patient exhibit statistically significant improvement in rigidity parameters of carotid femoral artery segments upon said administration.

### Claim 67 (depends on 57)

The method of claim 57, wherein said patient exhibits statistically significant reduction in mental asthenia upon said administration.

### Claim 68 (depends on 67)

The method of claim 67, wherein said administration of said combination leads to a statistically significant reduction in the mental asthenia by the MFI-20 scale in a suitable population of said patients in reference to the baseline.

### Claim 69 (depends on 57)

The method of claim 57, wherein said patient exhibits statistically significant reduction in general asthenia upon said administration.

### Claim 70 (depends on 69)

The method of claim 69, wherein said administration of said combination leads to a statistically significant reduction in the general asthenia by the MFI-20 scale in a suitable population of said patients in reference to the baseline.

### Claim 71 (depends on 57)

The method of claim 57, wherein said patient exhibits statistically significant reduction in anxiety associated with said asthenia and/or vegetative vascular dystonia upon said administration.

### Claim 72 (depends on 71)

The method of claim 71, wherein said administration of said combination leads to a statistically significant reduction in the trait anxiety as measured by Spielberg test in a suitable population of said patients in reference to the baseline.

### Claim 73 (depends on 57)

The method of claim 57, wherein said patient exhibits statistically significant reduction in depression associated with said asthenia and/or vegetative vascular dystonia upon said administration.

### Claim 74 (depends on 73)

The method of claim 73, wherein said administration of said combination leads to a statistically significant reduction in depression as measured by Beck test in a suitable population of said patients in reference to the baseline.

### Claim 75 (depends on 57)

The method of claim 57, wherein said patient exhibits statistically significant improvement in brachial artery dilation level upon said administration.

### Claim 76 (depends on 57)

The method of claim 57, wherein said activated-potentiated form of an antibody to a C-terminal fragment of the angiotensin II AT1 receptor is an antibody is a monoclonal, polyclonal or natural antibody.

### Claim 77 (depends on 76)

The method of claim 76, wherein said activated-potentiated form of an antibody to a C-terminal fragment of the angiotensin II AT1 receptor is a polyclonal antibody.

### Claim 78 (depends on 77)

The method of claim 77, wherein said activated-potentiated form of an antibody to a C-terminal fragment of the angiotensin II AT1 receptor is prepared by successive centesimal dilutions coupled with vertical shaking of every dilution.

### Claim 79 (depends on 57)

The method of claim 57, wherein said activated-potentiated form of an antibody to endothelial NO-synthase is an antibody is a monoclonal, polyclonal or natural antibody.

### Claim 80 (depends on 79)

The method of claim 79, wherein said activated-potentiated form of an antibody to endothelial NO-synthase is a polyclonal antibody.

### Claim 81 (depends on 1)

A method of treating hypertension comprising administering the combination of claim 1 to a patient in need thereof.

### Claim 82 (depends on 81)

The method of claim 81, further comprising concomitant administration to said patient of an additional therapeutic agent selected from the group consisting of ACE inhibitors, diuretics; β-adrenergic blockers, nitrates, cardiac glycosides, calcium antagonists, hypolipidemic agents, antiaggregants, antihypoxants, and anticoagulants.
